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Abstract
Background: Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues
of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two
other major global pathogens, Leishmania spp., responsible for leishmaniasis, and Trypansoma brucei, the causative agent of
African Sleeping Sickness. Both T. cruzi and Leishmania parasites have an essential requirement for ergosterol, and are thus
vulnerable to inhibitors of sterol 14a-demethylase (CYP51), which catalyzes the conversion of lanosterol to ergosterol.
Clinically employed anti-fungal azoles inhibit ergosterol biosynthesis in fungi, and specific azoles are also effective against
both Trypanosoma and Leishmania parasites. However, modification of azoles to enhance efficacy and circumvent potential
drug resistance has been problematic for both parasitic and fungal infections due to the lack of structural insights into drug
binding.
Methodology/Principal Findings: We have determined the crystal structures for CYP51 from T. cruzi (resolutions of 2.35 A ˚
and 2.27 A ˚), and from the related pathogen T. brucei (resolutions of 2.7 A ˚ and 2.6 A ˚), co-crystallized with the antifungal
drugs fluconazole and posaconazole. Remarkably, both drugs adopt multiple conformations when binding the target. The
fluconazole 2,4-difluorophenyl ring flips 180u depending on the H-bonding interactions with the BC-loop. The terminus of
the long functional tail group of posaconazole is bound loosely in the mouth of the hydrophobic substrate binding tunnel,
suggesting that the major contribution of the tail to drug efficacy is for pharmacokinetics rather than in interactions with
the target.
Conclusions/Significance: The structures provide new insights into binding of azoles to CYP51 and mechanisms of
potential drug resistance. Our studies define in structural detail the CYP51 therapeutic target in T. cruzi, and offer a starting
point for rationally designed anti-Chagasic drugs with improved efficacy and reduced toxicity.
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Introduction
Chagas Disease, a potentially lethal tropical infection, is caused
by the kinetoplastid protozoan Trypanosoma cruzi, which is spread
by blood-sucking reduviid insects [1]. It is the leading cause of
heart failure in Latin America, with an estimated to 8–10 million
people infected [2]. The parasite invades and reproduces in a
variety of host cells, including macrophages, smooth and striated
muscle, fibroblasts and neurons. Disease progression is marked by
an initial acute phase, which typically occurs in children, followed
by a symptom-free intermediate phase. A chronic phase leading to
GI tract lesions and heart failure often ensues. Current
chemotherapy options are limited to nifurtimox and benznidazole,
which have been in use since the late 1960s and are compromised
by adverse side reactions and low efficacy in chronic disease [3,4].
A need for drugs with more consistent efficacy and less toxicity is
manifest.
With an essential requirement for ergosterol [5] and an inability
to survive solely on cholesterol salvaged from the host, T. cruzi is
vulnerable to inhibitors of the sterol biosynthesis enzyme 14a-
demethylase (CYP51) [6,7]. Disruption of CYP51 results in
alteration in the ultrastructure of several organelles, decline of
endogenous sterols in the parasites, and an accumulation of
various 14a-methyl sterols with cytostatic and cytotoxic conse-
quences [8]. The broad spectrum antifungal drug posaconazole
(Noxafil; Schering-Plough) [9], which targets CYP51, is poised for
clinical trials against T. cruzi [6,10,11]. Posaconazole is capable of
inducing parasitological cure in a murine model of both acute and
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the acute phase of infection, and 50–60% of animals chronically
infected [7,11]. However, the high manufacturing cost of
posaconazole and the requirement for administration via oral
suspension simultaneously with a fatty meal or nutritional
supplement to enhance absorption may limit its use in treating
chronic T. cruzi infections [12]. The search for CYP51-specific
compounds that are easier to synthesize and better absorbed upon
oral administration continues [13–17].
To rationalize protein-ligand interactions for new inhibitors in
T. cruzi, homology modeling based on the x-ray structure of
CYP51 from Mycobacterium tuberculosis (CYP51Mt) [18–20] has been
used [14,15,17]. But CYP51Mt has only 27% sequence identity to
the T. cruzi enzyme and is unusually exposed to the bulk solvent at
the substrate binding site. This structural peculiarity largely
excludes the functionally important BC-loop from protein-
inhibitor interactions and thus limits the utility of CYP51Mt as a
model for a Chagas Disease target. The CYP51 BC-loop residue
105 (numbering according to T. cruzi and T. brucei CYP51) is
indispensable in the discrimination of the species-specific sterol
substrates in T. cruzi and T. brucei [19,21]. Also, a critical mutation
hot spot [22], the well conserved BC-loop residue Y116 was
reported to be involved in fungal drug resistance, inhibitor
binding, and the catalytic function of CYP51 in Candida albicans
(Y132, according to C. albicans numbering) [22–27], Histoplasma
capsulatum (Y136, according to H. capsulatum numbering) [28], and
in the causative agents of zygomycosis in humans, Rhizopus oryzae
and Absidia corymbifera [29]. It may therefore play a similar role in
T. cruzi.
Here we report the crystal structures for the CYP51 target in T.
cruzi (CYP51Tc) (resolutions 2.35 A ˚ and 2.27 A ˚) and that of the
closely related CYP51 ortholog from Trypanosoma brucei (CYP51Tb)
(resolutions 2.7 A ˚ and 2.6 A ˚), each bound to an anti-fungal
triazole drug, either fluconazole or posaconazole. T. brucei is a
protozoan parasite closely related to T. cruzi [30] and the agent of
another lethal tropical disease, African Sleeping Sickness. In
contrast to T. cruzi and Leishmania spp., it is not clear if the sterol
biosynthesis pathway can be targeted in T. brucei. Each parasite has
a different life-cycle and different sterol requirements. Although
the insect (procyclic) form of T. brucei can undertake de novo sterol
biosynthesis, the latter is apparently suppressed in the bloodstream
form in the mammalian host, which is supported by receptor-
mediated endocytosis of host low-density lipoproteins that carry
phospholipids and cholesterol esters [31]. Nevertheless, CYP51Tc
and CYP51Tb do share 83% sequence identity, a fact which has
been crucial for successfully determining their crystal structures
and makes it possible to extrapolate structural features learned
from one enzyme toward the other. Furthermore, the Leishmania
CYP51 are 72–78% identical to that of T. cruzi and T. brucei,s o
they too can now be modeled to facilitate drug discovery and
development.
Materials and Methods
Design of expression vectors
By trial-and-error we empirically identified the protein N-
terminal modification that eventually led to CYP51 crystals of
sufficient quality to determine the x-ray structure. To improve our
chances for success, we did the work in parallel on CYP51 proteins
from Trypanosoma cruzi and Trypanosoma brucei. Five different
expression vectors were designed in this work for each CYP51
ortholog to eliminate a stretch of hydrophobic residues which
presumably mediate association of the proteins with the endo-
plasmic reticulum (ER). In their place we introduced hydrophilic
or charged sequences at the N-terminus (Table 1). His6-tag
(CYP51Tc) or His8-tag (CYP51Tb) was introduced at the C-
terminus to facilitate purification. Coding sequences were sub-
cloned between the NdeI and HindIII restriction cloning sites of
the pCWori vector [32] and in this form used to transform
Escherichia coli strain HMS174(DE3). The original coding sequence
for CYP51Tb contained an internal NdeI site at 345 bp which
was silenced by QuickChange site-directed mutagenesis (Strata-
gene) using forward GGGGTTGCCTATGCTGCC and reverse
CCCCAACGGATACGACGG PCR primers. DNA amplifica-
tion reaction: 5 min at 94uC, annealing for 1 min at 50–60uC,
extension for 1.5 min at 72uC, for 30 cycles, followed by extension
for 10 min at 72uC. The highest expression levels were achieved
and the best crystals were obtained from the expression constructs
modified by replacing the first 21 residues upstream of K22 with
the fragment MAKKKKK. Subsequently, based on the analysis of
the packing interactions in the crystal, three consecutive glutamate
residues, E249-E251, were replaced inCYP51Tbwith alanine by site-
directed mutagenesis (Stratagene) using forward GCGCGGC-
TGCTGCTGTCAACAAGGACAGC and reverse GCGCG-
AGCAGCAGCCTTTCGAGCAATGAT PCR primers. DNA
amplification reaction: 5 min at 94uC, annealing for 1 min at 45–
65uC, extension for 1.5 min at 72uC, for 35 cycles, followed by
extension for 10 min at 72uC. This CYP51Tb variant was used to
generate the CYP51Tb-posaconazole crystals. The identity of all
resulting vectors was confirmed by DNA sequencing.
Protein expression and purification
CYP51Tc. One liter of Terrific Broth medium supplemented
with 1 mM thiamine, 100 mg/ml ampicillin and trace elements was
inoculated with 15 mlof the night culture. Growth continued at 37uC
and 240 rpm agitation until OD590 reached 1.0.CYP51Tcexpression
was induced by the addition of isopropyl-b-D-thiogalactopyranoside
(IPTG, final concentration 0.25 mM) and d-aminolevulinic acid, a
precursor ofhemebiosynthesis(finalconcentration1 mM).Following
induction, temperature was decreased to 28uC and agitation to
180 rpm. After 40 hours the cells were harvested and lysed by
Author Summary
Chagas Disease is caused by kinetoplastid protozoa
Trypanosoma cruzi, whose sterols resemble those of fungi,
in both composition and biosynthetic pathway. Azole
inhibitors of sterol 14a-demethylase (CYP51), such as
fluconazole, itraconazole, voriconazole, and posaconazole,
successfully treat fungal infections in humans. Efforts have
been made to translate anti-fungal azoles into a second-
use application for Chagas Disease. Ravuconazole and
posaconazole have been recently proposed as candidates
for clinical trials with Chagas Disease patients. However,
the widespread use of posaconazole for long-term
treatment of chronic infections may be limited by hepatic
and renal toxicity, a requirement for simultaneous intake of
a fatty meal or nutritional supplement to enhance
absorption, and cost. To aid our search for structurally
and synthetically simple CYP51 inhibitors, we have
determined the crystal structures of the CYP51 targets in
T. cruzi and T. brucei, both bound to the anti-fungal drugs
fluconazole or posaconazole. The structures provide a
basis for a design of new drugs targeting Chagas Disease,
and also make it possible to model the active site
characteristics of the highly homologous Leishmania
CYP51. This work provides a foundation for rational
synthesis of new therapeutic agents targeting the three
kinetoplastid parasites.
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centrifugation (45 min at 35,000 rpm). The supernatant was
subjected to a series of chromatographic steps, including nickel-
nitrilotriacetic acid (Ni-NTA) agarose (QIAGEN), followed by Q-
Sepharose (Amersham Biosciences) in flow-through regime, then by
S-Sepharose (Amersham Biosciences).From the S-Sepharose, protein
was eluted in a 0.2 to 1.0 M NaCl gradient and observed by means of
12% SDS-PAGE to be virtually homogeneous. Fractions containing
P450 werecombined, concentrated using a Centriprep concentrating
device (Millipore), and stored at 280uC. Twenty mM Tris-HCl,
pH 8.0, 10% glycerol, 0.5 mM EDTA, and 1 mM DTT were
maintained throughout all chromatographic steps.
CYP51Tb. In contrast to CYP51Tc, CYP51Tb yield was
significantly improved via co-expression of the E. coli chaperones
GroES and GroEL ecoded by the pGro7 plasmid (Takara) co-
transformed into the HMS174(DE3) strain. Double transformants
were selected on both ampicillin and chloramphenicol containing
agar plates. One liter of Terrific Broth medium supplemented
with 1 mM thiamine, 100 mg/ml ampicillin, 40 mg/ml
chloramphenicol and trace elements was inoculated with 10 ml
of the night culture. Growth continued at 37uC and 240 rpm
agitation until OD590 reached 0.2. Expression of chaperones from
the pGro7 vector was induced with 0.2% arabinose. Growth
continued at 26uC and 180 rpm until OD590 reached 0.8. Then
CYP51Tb expression was induced by the addition of isopropyl-b-
D-thiogalactopyranoside (IPTG), final concentration 0.4 mM; d-
aminolevulinic acid, final concentration 1 mM, was also added at
this time. Following induction, temperature was decreased to
21uC. After 44 hours the cells were harvested and lysed by
sonication. Purification was conducted as described for CYP51Tc.
Both proteins were characterized by UV-vis spectroscopy. For
crystallization, protein concentration was determined at 450 nm
from the difference spectra between the CO-bound ferrous and
water-bound ferric forms, with an extinction coefficient of
91,000 M
21cm
21 [33].
Crystallization and data collection
Screening of crystallization conditions was routinely performed
following purification of protein variants using commercial screening
kits available in high throughput screening format (Hampton
Research), a nanoliter drop-setting Mosquito robot (TTP Labtech)
operating with 96-well plates, and a hanging drop crystallization
protocol. Optimization of crystallization conditions, if required, was
carried out manually in 24-well plates at 23uC. Proteins were from
1.0–1.8 mM frozen stocks in 20 mM Tris-HCl, pH 7.2 (CYP51Tb)
or pH 8.0 (CYP51Tc), 10% glycerol, 0.5 mM EDTA, and 1 mM
DDT. The CYP51Tb triple mutant E249A/E250A/E251A was used
to obtain CYP51Tb-posaconazole crystals. Prior to crystallization
proteins were diluted to 0.1–0.2 mM by mixing with 50 mM
potassium phosphate at appropriate pH, supplemented with 0.5 mM
(CYP51Tb)o r0 . 1 m M( C Y P 5 1 Tc) fluconazole. Dilution in the
absence of fluconazole or phosphate caused fast precipitation of
protein samples.Posaconazole was prepared as 10 mMstock solution
in DMSO and has been used at final concentration of 0.2 mM.
Protein-posaconazole mix was incubated at 4uC for one hour prior to
crystallization. Crystals of CYP51Tb–fluconazole complex grew from
15% ethylene glycol and 0–3% acetonitrile. Crystals of CYP51Tb–
posaconazole complex grew from 6% PEG 4000, 2% tacsimate,
pH 8.0, and 2% DMSO. Crystals of CYP51Tc–fluconazole grew
either from 40% polypropylene glycol 400 and 0.1 M Tris-HCl,
pH 6.0 (PDB ID 2WUZ), or from 25% PEG 4000 and 0.1 M Bis-
Tris, pH 5.5 (PDB ID 2WX2), the latter being harvested directly
from the Mosquito 200-nl drop. Prior to data collection, the crystals
were cryo-protected by plunging them into a drop of reservoir
solution supplemented with 20–24% ethylene glycol or 20% glycerol,
a n df l a s h - f r o z e ni nl i q u i dn i t r o g e n .
All native and two-wavelength anomalous dispersion x-ray
diffraction data were collected at 100–110 K at beamline 8.3.1,
Advanced Light Source, Lawrence Berkeley National Laboratory,
USA. Anomalous diffraction data were collected from one
CYP51Tb crystal at two wavelengths, one corresponding to the
median between the Fe peak and the inflection point and the other
at 375 eV higher (Table 2). Data indexing, integration, scaling,
phasing, and density modification were conducted using the
ELVES automated software suite [34] (Tables 2 and 3).
Structure determination and refinement
CYP51Tb–fluconazole data processed in P3121 with Rmerge of
6.5% allowed for location of a single Fe atom. Initial phases with an
overall figure of merit of 0.26 were improved by solvent flattening
(mean figure of merit 0.85 after solvent flattening) to provide an
interpretable electron density map (Table 2). Automated model
Table 1. Design and analysis of the expression vectors.
Protein
Truncation
1 10 20 30 40 Yield Crystals
CYP51TcWT MFIEAIVLGLTALILYSVYSVKSFNTTRPTDPPVYPVTVP N/A No
CYP51Tc#1 MAKKTSSKGKL PPVYPVTVP 4 mg/l Yes
CYP51Tc#2 MA PPVYPVTVP N/A No
CYP51Tc#3 MA KSFNTTRPTDPPVYPVTVP N/A No
CYP51Tc#4 MAKKKKK KSFNTTRPTDPPVYPVTVP 75 mg/l Yes
CYP51Tc#5 MAKKKKK PPVYPVTVP 5 mg/l No
CYP51TbWT MLLEVAIFLLTALALYSFYFVKSFNVTRPTDPPVYPVTVP N/A No
CYP51Tb#1 MAKKTSSKGKL PPVYPVTVP 1 mg/l No
CYP51Tb#2 MAKKKKK KSFNTTRPTDPPVYPVTVP 3 mg/l Yes
CYP51Tb#3 MAKKTSSDEVDEVDEV DPPVYPVTVP N/A No
CYP51Tb#4 MADEVDEVDEV DPPVYPVTVP N/A No
CYP51Tb#5 MA PPVYPVTVP N/A No
Highlighted in bold are the constructs which led to the corresponding x-ray structures.
doi:10.1371/journal.pntd.0000651.t001
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for 84% of the residues in the asymmetric unit. The remaining
residues were built manually with COOT [36], alternated with TLS
and positional refinement using REFMAC [37,38]. The structure
was refined to 3.2 A ˚ with the R and Rfree values of 32.0% and 38.0%,
respectively. Although showing up largely as a polypeptide backbone
at low resolution, this T. brucei structure served as a search model for
molecular replacement in determining the x-ray structure for
CYP51Tc using 2.35 A ˚ native data processed as P21 with Rmerge of
11%. Two CYP51Tc molecules were placed in an asymmetric unit.
Manual model building with COOT [36] alternated with TLS and
positional refinement using REFMAC [37,38] resulted in the final
CYP51Tc structure with the R and Rfree= values of 21.7% and
27.5% and the Ramachandran statistics of 93.8% residues in
preferred regions, 5.2% in allowed regions, and 1% (9 residues)
outliers, as calculated by COOT. NCS restrains were applied at all
stages of the refinement. The refined CYP51Tc structure was used as
a startingmodel against both the 2.27 A ˚ native data for CYP51Tcand
2.7 A ˚ native data for CYP51Tb, which allowed the majority of the
CYP51Tb side chains to be built in. At that time, refinement of
CYP51Tb converged with R and Rfree of 21.0% and 27.4%,
respectively. Ramachandran statistics indicate 91.2% residues in
preferred regions, 5.9% in allowed regions, and 2.9% (13 residues)
outliers. Refinement of 2.27 A ˚ CYP51Tc data converged with R and
Rfree of 19.3% and 27.3%, respectively, and the Ramachandran
statistics of 95.6% residues in preferred regions, 3.5% in allowed
regions, and 0.9% (9 residues) outliers.
Analysis of the crystallographic symmetry packing interactions
in the CYP51Tb-fluconazole complex revealed contacts between
the triplets of glutamate residues D249-D251 situated in the GH-
loop. To reduce electrostatic repulsion, all three residues were
replaced with alanine. Although this modification did not improve
resolution of the CYP51Tb-fluconazole crystals, the triple mutant
was more amenable to co-crystallization with posaconazole. The
CYP51Tb coordinates refined to 2.7 A ˚ served as a search model to
determine CYP51Tb-posaconazole structure using 2.6 A ˚ native
data processed as C2 with Rmerge of 8.5%. Four protein molecules
were placed in an asymmetric unit. Refinement converged with R
and Rfree of 19.1% and 26.4%, respectively and the Ramachan-
dran statistics of 95.3% residues in preferred regions, 4.0% in
allowed regions, and 0.7% (13 residues) outliers. In all structures,
side chains not visible in the density were modeled as alanine
(Table 3).
Molecular docking
Binding of posaconazole to CYP51Tc was predicted by
molecular docking using the 2WUZ structure. Docking was
carried out using GLIDE (version 5.0) [39]. The docking protocol
was validated by re-docking of fluconazole, which reproduced the
binding mode observed in the crystal structure. The protein was
initially prepared by the Protein Preparation Wizard module using
default options. Hydrogen atoms were added to the complex
structure, followed by a restrained minimization using the
OPLS2005 force field. The Receptor Grid Generation module
was then employed to prepare a rigid receptor grid centered at
M360, which contains the entire binding tunnel of the energy
minimized complex, for subsequent docking. The three-dimen-
sional structure of posaconazole was generated by the Ligprep
module with the OPLS2005 force field. Computational docking
was performed using GLIDE in standard precision (SP) mode, and
binding affinities were estimated as GLIDE score. The character-
istic coordination between the heme group and the ligand was
modeled by applying a constraint at the Fe
3+ ion of the heme
group that imposed interaction with one of the nitrogen atoms
from the ligand’s triazolyl ring. Since posaconazole (molecular
weight=700.8 g/mol) is significantly larger and longer than
fluconazole (molecular weight=306.3 g/mol) (Fig. 1), the van
der Waals radii of the ligand were softened by a scaling factor of
0.6 in the initial docking calculation, which predicted two binding
poses with similar Glide scores of 29.23 and 29.60. The binding
model was further refined by relaxing the binding tunnel in the
presence of posaconazole. Side chains of residues within 4 A ˚ from
the docked posaconazole were optimized by performing side-chain
refinement with Prime (version 2.0) [40]. The resulting complex
was used to re-dock posaconazole with van der Waals radii scaled
by the default value of 0.8. Consistent with the initial calculations,
the second-round docking also predicted the same binding
orientations with favorable and similar GLIDE scores (pose
1=211.07; pose 2=210.70).
Accession codes
Protein Data Bank: coordinates and structure factors have been
deposited with accession codes 2WUZ, 2WX2, 2WV2 and 2X2N.
Results and Discussion
Protein design and determination of the x-ray structures
By trial-and-error, the highest expression levels and best crystals
for both CYP51Tc and CYP51Tb were obtained from the
expression constructs modified by replacing the first 21 residues
upstream of K22 with the highly positively charged fragment
MAKKKKK (Table 1). The triple E249A/E250A/E251A
CYP51Tb mutant was based upon this N-terminally modified
construct. The UV-vis spectra of purified proteins revealed
Table 2. Fe anomalous dispersion data collection and
phasing statistics.
Protein CYP51Tb
Ligand Fluconazole
Data collection
Space group P3121
Cell dimensions
a, b, c (A ˚) 106.4, 106.4, 99.8
a, b, c (u) 90, 90, 120
Molecules in AU 1
Peak/Inflection Remote
Wavelength 1.7393 1.6531
Resolution (A ˚) 3.2 3.2
Rsym or Rmerge (%) 6.5 (–)
1 6.2 (–)
I/sI 21.1 (2.3) 22.4 (2.9)
Completeness (%) 100 (93.4) 100 (99.1)
Redundancy 18.8 (9.5) 20.2 (13.0)
Phasing
Resolution range 3.2–67.7
No. of used sites 1
Phasing power 0.38 0.36
Figure of merit 0.26
After density modification 0.85
1Values in parentheses are for highest-resolution shell; Rsym is meaningless
when the individual spot I/sI value is below 1.
doi:10.1371/journal.pntd.0000651.t002
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(Fig. 2). We first determined the crystal structure for CYP51Tb
using anomalous dispersion of the heme iron. Although largely a
backbone trace at 3.2 A ˚ resolution, this structure served as a
search model for molecular replacement in determining the
CYP51Tc–fluconazole structure at 2.35 A ˚, which was used as a
search model against the 2.27 A ˚ CYP51Tc–fluconazole data to
reveal an alternative conformation of fluconazole bound in the
active site. This same CYP51Tc structure was used as a model
against the 2.7 A ˚ CYP51Tb–fluconazole data. Refined to 2.7 A ˚
CYP51Tb coordinates subsequently served as a search model for
determining the 2.6 A ˚ CYP51Tb–posaconazole structure.
Overall crystal structures of CYP51
CYP51Tc and CYP51Tb have a common P450 protein fold
characterized by the sets of the a-helices and b-sheets highlighted
in Fig. 3A, B. The T. cruzi and T. brucei structures superimpose
with r.m.s.d. of 0.89 A ˚ for Ca atoms, with the most pronounced
Table 3. Data collection and refinement statistics.
Native
Protein CYP51Tc CYP51Tc CYP51Tb CYP51Tb
Ligand Fluconazole Fluconazole Fluconazole Posaconazole
PDB ID 2WX2 2WUZ 2WV2 2X2N
Data collection
Space group P21 P21 P3121 C2
Cell dimensions
a, b, c (A ˚) 70.0, 101.5, 74.7 74.9, 92.6, 78.3 106.2, 106.2, 99.7 199.9, 114.5, 138.1
a, b, c (u) 90, 111.63, 90 90, 102.1, 90 90, 90, 120 90, 131.8, 90
Molecules in AU 2 2 1 4
Wavelength 1.1159 1.1159 1.1159 1.1159
Resolution (A ˚) 2.27 2.35 2.7 2.6
Rsym or Rmerge (%) 9.0 (42.0)
1 11.0 (50.0) 10.7 (–)
2 8.5 (76.9)
I/sI 8.5 (2.4) 7.4 (1.5) 17.0 (2.8) 9.2 (1.7)
Completeness (%) 100.0 (55.7) 93.6 (70.8) 100.0 (100.0) 99.8 (100.0)
Redundancy 3.6 (2.4) 3.4 (2.4) 44.1 (44.5) 3.9 (3.9)
Phasing
Resolution range
No. of used sites
Phasing power
Figure of merit
After density modification
Refinement
No. reflections 38067 38792 17043 71168
Rwork/Rfree (%) 19.3/27.3 21.7/27.5 21.0/27.4 19.1/26.4
No. atoms
Protein 6954 6994 3433 14048
Heme 86 86 43 172
Ligand 44 44 22 204
Water 429 179 15 253
Mean B value 23.7 44.6 45.8 53.9
B-factors
Protein 23.8 44.9 37.2 54.2
Heme 15.5 41.6 65.0 47.7
Ligand 32.1 47.0 93.1 50.7
Water 25.3 43.5 36.6 46.4
R.m.s deviations
Bond lengths (A ˚) 0.016 0.019 0.018 0.016
Bond angles (u) 1.7 1.9 1.8 1.7
1Values in parentheses are for highest-resolution shell.
2Rsym is meaningless when the individual spot I/sI value is below 1.
doi:10.1371/journal.pntd.0000651.t003
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loop between them (Fig. 4A). By contrast, Trypanosoma CYP51
enzymes do not superimpose nearly as well with bacterial
CYP51Mt (r.m.s.d. of 1.83 A ˚) (Fig. 4B), being more similar to
their human counterpart (CYP51h), based on both backbone
similarity (r.m.s.d. of 1.45 A ˚) and solvent exposure at the active site
(Fig. 4C). All three eukaryotic enzymes lack the extreme bending
of the I-helix that is associated with CYP51Mt, resulting in their
active sites being more isolated from the bulk solvent. The
structured BC-region in Trypanosoma CYP51 includes the B’-helix
encompassed by the short g-helices blocking access to the active
site from the bulk solvent. Seven residues from the BC-region,
V102, Y103, I105, M106, F110, A115 and Y116, are part of the
active site in CYP51Tc and CYP51Tb, which is consistent with our
previous observation that a series of CYP51 inhibitors reported
elsewhere [16] have higher binding affinities toward Trypanosoma
CYP51 compared to CYP51Mt, where these residues do not
participate in the active site due to the ‘‘open’’ conformation of the
loop. The two CYP51Tc–fluconazole structures reported here
superimpose with r.m.s.d of 0.68 A ˚, revealing some conforma-
tional differences in the F-helix and the BC-loop, which may
account for the distinct fluconazole binding modes and result in re-
packing of protein molecules in the crystal lattice (Table 3).
In the CYP51Tb-posaconazole structure, four protein molecules in
the asymmetric unit superimpose with the r.m.s.d. within of 0.5 A ˚,
revealing virtually no conformational variations. However, posaco-
nazole samples two distinct conformations due to the long tail
swinging ,7–8 A ˚ in the hydrophobic mouth of the substrate binding
tunnel (Fig. 3B). The entrance to the tunnel is marked by a patch of
the hydrophobic residues (colored yellow in Fig. 3B), which
apparently guide access of the sterol substrates to the active site.
Fluconazole binding in the active site
As expected, fluconazole is bound in the active site by
coordination to the heme iron via the aromatic nitrogen atom of
a triazole ring and by multiple van der Waals and aromatic
stacking interactions (Fig. 5). All residues within 7 A ˚ of fluconazole
(Fig. 6A) are labeled with blue triangles in Fig. 7. The 2,4-
difluorophenyl moiety is enclosed in the pocket formed by the
heme macrocycle, the aromatic side chains of Y103, F110, Y116
(BC-loop) and F290 (I-helix), and aliphatic side chains M106,
A287 and A291. Although fluconazole occupies the same pocket
in both CYP51Tc structures, it adopts two conformations that
differ by the 180u flipping of the 2,4-difluorophenyl moiety.
Orientation 1 is observed both in the 2.27 A ˚ CYP51Tc–
fluconazole structure reported in this work (PDB ID 2WX2)
(Fig. 5A) and in the CYP51Mt-fluconazole complex reported
elsewhere (PDB ID 1EA1) [18]. The same conformation is
adopted by the 2,4-difluorophenyl ring of posaconazole in the
CYP51Tb-posaconazole complex in all four molecules in the
asymmetric unit. In orientation 1, Y103 makes a 2.7 A ˚ H-bonding
contact to the main chain amide group of M360. A 180u flipped
orientation of the ring, orientation 2, is observed in the 2.35 A ˚
CYP51Tc–fluconazole structure (PDB ID 2WUZ) (Fig. 5B). As
evidenced by the residual Fo-Fc electron density map calculated for
Figure 2. Spectral characterization of CYP51Tc and CYP51Tb. Soret and visible regions of the CYP51Tc (A) and CYP51Tb (B) spectra are shown.
The ferric protein (dashed trace) was reduced with sodium dithionite to a ferrous form (solid trace) in the presence of CO. The spectra were recorded
at room temperature in a 1 ml quartz cuvette containing 1 mM CYP51 in 10 mM Tris-HCl, pH 7.5, and 10% glycerol using a Cary UV-visible scanning
spectrophotometer (Varian). CYP51Tc has a Soret maximum at 420 nm which upon reduction with sodium dithionite and CO binding shifts to 449 nm
(A). CYP51Tb has a Soret maximum at 417 nm which upon reduction and CO binding shifts to 446 nm (B).
doi:10.1371/journal.pntd.0000651.g002
Figure 1. Chemical structures of posaconazole and fluconazole.
doi:10.1371/journal.pntd.0000651.g001
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the fluconazole difluorophenyl ring in 2WUZ must point toward
the heme macrocycle. A 2.6 A ˚ H-bonding contact between the 2-
fluoro substituent and the hydroxyl group of Y103 may help to
stabilize orientation 2, which appears to be less sterically favorable
than orientation 1.
Perhaps both ring conformations co-exist in the CYP51Tc-
fluconazole complex, possibly correlated with the conformation of
the BC-loop which affects H-bonding pattern of Y103. In
orientation 1, the H-bond between the 2-fluoro substituent and
Y103 is broken due to the 3.5 A ˚ reorientation of Y103 toward
M360 resulting in the 2.7 A ˚ H-bond to its amide nitrogen and in
the flipping of the 2,4-difluorophenyl ring into a sterically more
favorable orientation with the fluorinated edge facing away from
the heme macrocycle (Fig. 5B). Crystallization conditions may
have served to shift the equilibrium by stabilizing one of these
states. The entire fluconazole molecule is shifted about 1.5 A ˚
between the two CYP51Tc structures, which may be related to the
low efficacy of this drug against T. cruzi. Given that the CYP51Tb
active site is virtually identical to that of T. cruzi, the same
equilibrium would be expected to occur in T. brucei. However, we
could not observe this phenomenon as CYP51Tb-fluconazole
complex has been co-crystallized under a single set of conditions
with one molecule in the asymmetric unit.
Hydrophobic tunnel
The CYP51Tc structures revealed a 42 residue-long hydropho-
bic tunnel connecting the chamber adjacent to the heme with the
Figure 3. Overall structures of CYP51. A, B. Fluconazole-bound CYP51Tc with selected a-helices labeled (PDB ID Code 2WUZ). A. Distal protein
surface with respect to heme. B. Image is rotated ,90u toward viewer. Protein backbone is depicted by cyan ribbon with the I-helix highlighted in
magenta, BC-region in green, FG-region in blue. Heme (orange) and fluconazole are depicted by spheres. Fluconazole color scheme: carbon yellow,
oxygen red, nitrogen blue, fluorine cyan. Images were prepared using PYMOL [58] unless indicated otherwise. C, D. CYP51Tb in surface
representation with the hydrophobic residues colored in golden yellow. In C, posaconazole is omitted for clarity, heme prosthetic group (pink) shows
through the hydrophobic tunnel entrance. In D, two overlaid posaconazole conformers are shown protruding out of the tunnel opening. Bent
conformer (chain B) is in red, extended conformer (chain D) is in blue. Images were generated using VMD program [59].
doi:10.1371/journal.pntd.0000651.g003
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www.plosntds.org 7 April 2010 | Volume 4 | Issue 4 | e651Figure 4. Comparison between CYP51 from different phyla. A. CYP51Tc (cyan in A, B and C, PDB ID Code 2WUZ) and CYP51Tb (wheat, PDB ID
Code 2WV2) superimposed with r.m.s.d. of 0.89 A ˚. Helices are represented by labeled cylinders. Fluconazole is omitted for clarity. B. CYP51Tc and
CYP51Mt (golden yellow, PDB ID Code 2VKU) superimposed with r.m.s.d of 1.83 A ˚. C. CYP51Tc and CYP51h (lemon green, PDB ID Code: 3I3K)
superimposed with r.m.s.d of 1.45 A ˚. In each panel, distal surface is shown on the right. Image on the left is rotated ,90u toward viewer.
doi:10.1371/journal.pntd.0000651.g004
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addition to those interacting with fluconazole are labeled with
green triangles in Fig. 7. The mouth of the channel is surrounded
by residues I45, I46, G49, K50, I209, P210, H458, and M460,
which may delineate the substrate/inhibitor entry site in
eukaryotic CYP51 (Fig. 8). This entry mode would be in contrast
to that in CYP51Mt, where it most likely occurs through the open
BC-loop. The tunnel-forming residues are invariant between
CYP51Tc and CYP51Tb with the exception of four conservative
substitutions at positions 46, 105, 215 and 359. The residue at
position 105 (highlighted cyan in Fig. 7) is known to dominate
substrate specificity with respect to the methylation status of the C-
4 atom in CYP51 sterol substrates. I105 in T. cruzi allows efficient
conversion of C4-dimethylated 24-methylenedihydrolanosterol
while the bulkier F105 in T. brucei favors C4-monomethylated
norlanosterol [19,21]. Phenylalanine in CYP51Tb protrudes
further into the active site than isoleucine in CYP51Tc (Fig. 6A),
potentially resulting in interference with the 4b-methyl group of
the sterol substrate. However, F105 does not interfere with either
posaconazole or fluconazole binding.
Comparison of the residues constituting the tunnel in CYP51Tc
with the human counterpart, CYP51h, indicates that two residues,
H236 and H489 (numbered according to the human sequence and
highlighted yellow in Fig. 7), protrude into the tunnel near the
opening, reducing both its size and hydrophobicity. As they are
present exclusively in mammalian orthologues [41], H236 and
H489 may partly account for the selectivity of azole drugs toward
pathogenic fungi and protozoa. In accord with this hypothesis,
proline corresponding to H236 in pathogenic fungi is among hot
spots that confer resistance to posaconazole in Aspergillus fumigatus
(P216) [42] and Candida albicans (P230) [43].
Posaconazole binding
The hydrophobic tunnel in CYP51Tb accommodates the
antifungal drug posaconazole in either extended or bent
conformations. The 2.6 A ˚ structure of the CYP51Tb-posaconazole
Figure 5. Fluconazole binding in CYP51Tc.A ,B .Stereoscopic view of CYP51Tc with fluconazole bound in active site. Side chains of the residues
within 4 A ˚ of fluconazole are in green. For clarity, A287, A291 and T295 are omitted. Main chain atoms are shown for M360. Fluconazole color scheme
as in Fig. 3. Fragments of 2Fo-Fc electron density map calculated with the fluconazole coordinates omitted from the input file are shown as grey wire
mesh. Chain A has been used in both structures to generate the images. A. Fluconazole orientation 1 in 2WX2 structure; OH-group of Y103 H-bonds
to the amide nitrogen of M360. B. Fluconazole orientation 2 in the 2WUZ structure; peak in the positive Fo-Fc map (pink mesh) calculated with 2,4-
difluorophenyl ring in flipped orientation superimposes with the 2-fluorine H-bonding to Y103.
doi:10.1371/journal.pntd.0000651.g005
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with posaconazole coordinating to the heme iron in a manner
similar to that of fluconazole with the fluorinated edge of the 2,4-
difluorophenyl ring facing away from the heme macrocycle, and
the long substituent tail extending into the hydrophobic tunnel.
Electron density is well defined for the Fe-coordinating head of the
posaconazole molecule in all four monomers but somewhat fades
out toward its long tail (Fig. 8A). Thus, the terminal 2-
hydroxypentan group is defined in none of four monomers. Three
from the four monomers (chains A, B, and C) accommodate
posaconazole in bent conformation while in the monomer D
posaconazole is in extended conformation. Conformational
variability of posaconazole is enabled by the interconversion of
the piperazine six-membered ring between the chair and twisted
boat conformations. The latter serves to accommodate the bend.
Electron density is best defined in monomer B, where the terminal
phenyl-2-hydroxypentan-triazolone group of posaconazole lies
within 6 A ˚ of protein residues I209-P210-A211 and V213-F214
which are invariant between CYP51Tc and CYP51Tb. P210, the
mutation hot spot in fungi, is situated right in the bend of the
posaconazole molecule (Fig. 9A). In the extended conformation in
monomer D, the phenyl-2-hydroxypentan-triazolone group swings
toward residues I45-I46 (Fig. 9B). Remarkably, points of
posaconazole contact in the tunnel mouth are among mutation
hot spots in azole resistant isolates of pathogenic fungi A. fumigatus
[42,44–48] and C. albicans [43,49] (Fig. 8B and C).The scattered
Fo-Fc electron density map in the monomers A and D (Fig. 8A)
suggests possible interconversion of the posaconazole conformers
in dynamic equilibrium, meaning that the phenyl-2-hydroxypen-
tan-triazolone group dangles in space within the tunnel mouth
(Fig. 3D). Given the high sequence and structural similarities
between CYP51Tc and CYP51Tb, similar dynamics would be
expected in the CYP51Tc-posaconazole complex.
Docking studies
The x-ray structures of the CYP51 therapeutic targets
determined in this work are intended for use in rational drug
design. We also apply computational methods to explore binding
modes of known chemical structures as well as to generate new
scaffolds based on the configuration of the CYP51 binding sites.
Considering the differential geometries of the host and pathogen
binding sites, we aim to develop a pool of highly selective
molecules with no cross-reactivity to human CYP51. As a first
step, we docked posaconazole into the CYP51Tc active site and
compared the docking poses with the experimental structure of
CYP51Tb-posaconazole complex. Two poses with similar docking
scores were identified for posaconazole by GLIDE [39], differing
primarily in the orientation of the 2,4-difluorophenyl ring (Fig. 10).
Interestingly, the long posaconazole tail docks in a mode more
similar to the CYP51Tb-posaconazole complex defined in this
work rather than that in the recently deposited T. cruzi structure
(PDB ID Code: 3K1O). Given that the protein-posaconazole
interactions in the tunnel are of hydrophobic/aromatic stacking
nature (Fig. 9), this ambiguity is not surprising.
Another source of docking ambiguity arises from the binding
predicted for the 2,4-difluorophenyl substituent. In the better
scoring pose 1 (highlighted yellow in Fig. 10), the 2,4-
difluorophenyl ring binds in the experimentally observed orienta-
tion 1. In the slightly lower scoring pose 2 (highlighted pink), the
2,4-difluorophenyl ring is bound in a different pocket formed by
the residues M106, E205, L208, F290, T295, L358 and M460,
suggesting an additional cavity in the CYP51 active site suitable
for drug targeting. This pose is achieved via flipping of the central
furan ring to which all the substituents are attached. Thus, in
addition to the experimentally observed binding ambiguity of the
long substituent tail, conformational ambiguity of the difluor-
ophenyl ring is predicted by the docking calculations and perhaps
will be observed in future structures of CYP51 in complex with
inhibitors similar to posaconazole.
Implications for drug resistance
The rapid development of azole resistance in T. cruzi observed in
vitro suggests that the same may occur in patients [50]. Although
no data are available on the development of posaconazole
resistance in Chagas Disease patients, studies conducted on fungal
infections indicate that posaconazole resistance occurs mainly by a
mechanism involving mutation of the cyp51 gene [42,51,52].
Posaconazole appears to be less susceptible to the efflux pumps
that confer resistance to some other azoles [43,51,53]. Mapping
mutations in cyp51 genes in clinical posaconazole resistant isolates
on the CYP51 structure, points to the tunnel entrance as a
mutation hot spot. Mutations of G54, P216 and M220 in clinical
Figure 6. Hydrophobic tunnel. A. Fluconazole in orientation 2 bound to CYP51Tc. Fluorinated edge of the 2,4-difluorophenyl ring faces heme
macrocycle. Fluconazole and heme are shown as van der Waals spheres; residues within 7 A ˚ of fluconazole as sticks. Color scheme for heme and
fluconazole as in Fig. 3. F105 superimposed from CYP51Tb is shown as semitransparent pink spheres. B. Front view of CYP51Tc clipped by plane
(cyan) through substrate binding tunnel. Hydrophobic areas are orange, hydrophilic areas blue. Heme at end of tunnel: with van der Waals spheres in
red. Fluconazole is removed for clarity. Image was prepared using CHIMERA [60].
doi:10.1371/journal.pntd.0000651.g006
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F214, respectively, in CYP51Tc and CYP51Tb) and of A61 [49]
and P230 [43] in clinical isolates of C. albicans (I45 and P210,
respectively, in CYP51Tc and CYP51Tb) map directly to the tunnel
mouth (Fig. 8B and C). Mutations of G54 in A. fumigatus to
arginine or tryptophan associate with moderate and high levels of
resistance, respectively, and confer cross-resistance between
itraconazole and posaconazole [44]. Mutations of M220 confer
cross-resistance to all azole drugs tested, including itraconazole,
voriconazole, ravuconazole and posaconazole [54,55] and there-
fore may interfere with the entry of the drugs. In accord with this
assumption, posaconazole is reported to induce resistance to all
Figure 7. Sequence alignments between host and pathogen CYP51. Sequence alignments between CYP51 from Trypanosoma cruzi,
Trypanosoma brucei, Aspergillus fumigatus, Candida albicans and human. Accession numbers of the proteins in the Swiss-Prot/TrEMBL (http://us.
expasy.org/sprot) and NCBI (http://www.ncbi.nlm.nih.gov/) databases are given next to the name of the protein. Alignments were performed using
CLUSTALW program online [61]. The figure was generated using ESPript [62]. The secondary structure annotation and residue numbering at the top
correspond to CYP51Tc, residue numbering at the bottom corresponds to human CYP51. The a-helices are labeled with capital letters according to
generally accepted P450 nomenclature. The b-strands of large b-sheets are labeled with dashed numbers. Sequential numbers are used to label short
two-residue b-strands. Residues within 7 A ˚ of fluconazole are labeled with blue triangles. Additional residues constituting the hydrophobic tunnel are
labeled with green triangles. Human H236 and H489 and the corresponding residues in the pathogenic species are highlighted in yellow. Residues
corresponding to CYP51Tc I105 are highlighted in cyan. Mutation hot spots at the tunnel opening are marked with black stars. Gray stars highlight
residues in alternate conformations.
doi:10.1371/journal.pntd.0000651.g007
Figure 8. Posaconazole conformation. A. Fragments of the Fo-Fc electron density map (grey mesh) in chains A, B and D calculated with the
posaconazole coordinates omitted from the input file. B, C. Posaconazole protruding from the tunnel entrance is shown in the chain B (B) and chain
D( C). Protein backbone is depicted by yellow ribbon, protein surface is represented by black mesh, residues surrounding tunnel entrance (cyan) are
in stick mode. Arrows point at the residues corresponding mutation hot spots in posaconazole resistant isolates of A. fumigatus and C. albicans.
Posaconazole is shown by spheres with the carbon atoms white, oxygen red, nitrogen blue, fluorine light green. Heme in the background is orange.
K50 side chain is not defined in the electron density and therefore modeled as alanine. Images were prepared using MAESTRO [63].
doi:10.1371/journal.pntd.0000651.g008
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perspective emerging from antifungal therapy efforts must be
taken into consideration when designing anti-Chagasic drugs
targeting CYP51Tc. Thus, the terminal phenyl-2-hydroxypentan-
triazolone group in posaconazole may play an important role in
pharmacokinetics rather than in the interactions with the target,
and yet these interactions seem to induce resistance which
otherwise could probably be avoided.
In summary, the x-ray structures of Trypanosoma CYP51
enzymes reported here open new opportunities for rationally
designed inhibitors against therapeutic targets in important human
pathogens. The structures provide templates for developing
CYP51 inhibitors with improved efficacy and resistance properties
that are structurally and synthetically simpler than posaconazole.
By utilizing the differential geometries between host and pathogen
CYP51 binding sites, it maybe possible to create new drugs with
minimized toxicity and host-pathogen cross-reactivity. In addition,
the posaconazole binding mode offers insights into the develop-
ment of drug resistance in pathogenic fungi, implying that an
analogous mechanism may be implicated in protozoan pathogens.
The reported structures also provide a good template for drug
design targeting Leishmania CYP51. However, drug development
must take into account the properties and accessibility of the
compartment where these parasites reside. Unlike T. cruzi,
Leishmania amastigotes replicate in the acidic environment (pH
,5) of the phagolysosomal vacuoles in macrophage cells [56,57],
imposing different requirements on the physicochemical properties
of CYP51 inhibitors targeting leishmaniasis.
Figure 9. Posaconazole binding. Stereoscopic view of posaconazole in chain B (A) and in chain D (B) surrounded by the side chains within 4 A ˚.
Image in B is rotated ,90u to the right along the vertical axis in the plane of drawing. To avoid image cluttering, four residues from this range, Y103,
Y116, A211 and M360, were excluded from the view in A. Posaconazole carbons are highlighted in yellow, amino acid residues are in green.
Otherwise color scheme is as in Fig. 8.
doi:10.1371/journal.pntd.0000651.g009
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